What I am basically saying is that, in my opinion, this settlement didn't change the risk at all. Its just one more generic (now 2, Teva being the other) that can launch 6 months prior to the patents expiring. That is 9 years down the road. The entire risk in this stock currently lays on the back of the outcome of the appeal. The patents involved are only for the US, we still have the rest of the world we can sell to, with vastly different patent laws. So, to make a long story a little longer, this settlement does nothing to change the risk, IMHO.
News 
Market Data 
Discover 
